ライフサイエンスコーパス: MSSA

1 MSSA accounted for 59.7% of healthcare-associated cases

2 MSSA IE isolates were significantly more likely to be CC

3 MSSA isolates belonged to 17 sequence type (ST) groups.

4 MSSA isolates from colonized or VAT patients exhibited s

5 MSSA recovery also increased significantly when using br

6 MSSA showed no collective inter-annual patterns of oscil

7 MSSA strains with strong blood agar hemolysis and high a

8 e bottles (identified as 10 MRSA strains, 10 MSSA strains, 12 coagulase-negative Staphylococcus strai

9 A cases were matched to 207 controls and 112 MSSA cases to 208 controls.

10 s included 59 patients with SaB (47 MRSA, 12 MSSA) from 2015-2017.

11 Within common MRSA clonal complexes, 3/14 MSSA and 2/21 PSSA isolates arose from the loss of resis

12 A total of 21 MSSA isolates and 37 MRSA isolates recovered from infect

13 rmed abscess were identified: 30 MRSA and 24 MSSA.

14 Among a sample of 252 MSSA isolates from the United States and Europe, 3.9% co

15 Within CC8, all 38 MRSA (USA300) and all 28 MSSA isolates harbored the R variant.

16 had 3978 invasive S aureus infections (2868 MSSA and 1110 MRSA).

17 lates (8.0%) (MRSA, 18/173 isolates [10.4%]; MSSA, 5/114 isolates [4.4%]).

18 % [SCCmec II], 8.3% [other MRSA], and 15.6% [MSSA]).

19 and hand carriage was found in 24.9% (20.7% MSSA and 4.1% MRSA).

20 y identified culture controls for MRSA (76), MSSA (12), and confounder organisms (36) with 100% sensi

21 A total of 93 MSSA isolates and 2 MRSA isolates were recovered from 15

22 A recurrent infection was defined as a MSSA blood culture between 45 and 365 days after the fir

23 anc results in the fewest patients achieving MSSA cure and the highest rate of recurrence (67.3%/14.8

24 te that ceftaroline is highly active against MSSA and MRSA isolated from US medical centers, independ

25 nem provides potent in vivo activity against MSSA beyond what is predicted in vitro and warrants furt

26 When tested against MSSA, levofloxacin resistance was higher among isolates

27 Among MSSA-bacteremic patients who did not die or get hospital

28 nt predictor for incision and drainage among MSSA strains.

29 ong MRSA of PFGE type USA300, was rare among MSSA USA300 in both time periods.

30 In total, 124 patients had an MSSA osteoarticular infection; 64 (52%) had orthopedic h

31 nd Multi-channel Singular Spectrum analysis (MSSA) methods are applied, on the shoreface, to three po

32 We detected MRSA (n = 240) and MSSA (n = 119) in 22 of 44 (50%) and 24 of 44 (55%) wast

33 us type IVa (13.5%), other MRSA (12.5%), and MSSA (8.9%).

34 on), antibacterial activity against MRSA and MSSA and cytotoxicity against NCI-H460, MCF-7 and HeLa.

35 This study demonstrates that MRSA and MSSA can be accurately differentiated by FCM after 2 h o

36 this study was to determine whether MRSA and MSSA could be reliably differentiated by FCM.

37 We evaluated MRSA and MSSA endotracheal aspirates (ETA) for genotype and alpha

38 no significant differences between MRSA and MSSA HCAP patients in mortality (29% versus 20%, respect

39 bal SERS-based dendrogram model for MRSA and MSSA identification and differentiation to the strain le

40 incidence of HO-SAB caused by both MRSA and MSSA in Australian hospitals since 2002.

41 Infant mortality after invasive MRSA and MSSA infections is similar, but MSSA causes more infecti

42 ffer between patients who developed MRSA and MSSA infections.

43 ety-three percent and 29% of unique MRSA and MSSA isolates, respectively, were multidrug resistant.

44 de) were active against 24 clinical MRSA and MSSA isolates.

45 The relative proportions of MRSA and MSSA skin culture isolates were measured, along with ant

46 Samples were analyzed for MRSA and MSSA using membrane filtration.

47 eus (including clinical isolates of MRSA and MSSA) and Staphylococcus epidermidis identified one cand

48 isolates of Staphylococcus aureus (MRSA and MSSA) with 89+/-0.1% accuracy.

49 overall with no difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacte

50 oresis (CZE) to distinguish between MRSA and MSSA.

51 r detection of bacteremia caused by MRSA and MSSA.

52 FE acted as a moderate inhibitor of MRSA and MSSA.

53 range of S. aureus, including both MRSA and MSSA.

54 ially passaged clinical isolates of MRSA and MSSA.

55 ) methicillin-resistant S. aureus (MRSA) and MSSA SSTIs were comparable.

56 d pneumonia infections, as well as MRSA- and MSSA-related infections from conditions classified elsew

57 ts for hospitalizations, including MRSA- and MSSA-related septicemia and pneumonia infections, as wel

58 Patients who were MRSA-negative and MSSA-negative bathed with CHG the night before and morni

59 nd that the patterns extracted using SSA and MSSA agree well with previous patterns identified using

60 ified empty-cassette strains of S. aureus as MSSA.

61 .7% sensitivity; 904/907) were classified as MSSA by the BD Max StaphSR assay, due to negative result

62 The 23 recovered isolates were confirmed as MSSA by a variety of phenotypic methods, including the B

63 maining isolates were not MRSA and tested as MSSA by phenotypic and genotypic assays.

64 h a major community- and hospital-associated MSSA pathogen in the Dominican neighborhood of northern

65 ldren with methicillin-susceptible S aureus (MSSA) treated with vancomycin compared with 2.6% (22 of

66 hicillin-sensitive and -resistant S. aureus (MSSA and MRSA) that may influence host colonization and

67 eptible and methicillin-resistant S. aureus (MSSA and MRSA, respectively) in samples taken directly f

68 nts to be methicillin-susceptible S. aureus (MSSA) (74/84 [88.1%] versus 56/106 [52.8%], respectively

69 e against methicillin-susceptible S. aureus (MSSA) (MIC(50), 0.25 mug/mL; MIC(90), 0.25 mug/mL; 100.0

70 MRSA) and methicillin-susceptible S. aureus (MSSA) among all CAP episodes.

71 (83%) had methicillin-susceptible S. aureus (MSSA) and 73 (17%) had methicillin-resistant S. aureus (

72 isodes of methicillin-susceptible S. aureus (MSSA) and 875 episodes of methicillin-resistant S. aureu

73 h MRSA or methicillin-susceptible S. aureus (MSSA) and control children infected with influenza virus

74 luated HO methicillin-susceptible S. aureus (MSSA) and HO methicillin-resistant S. aureus (MRSA) BSIs

75 t against methicillin-susceptible S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA).

76 iation of methicillin-susceptible S. aureus (MSSA) and MRSA directly from positive blood cultures has

77 fferentiate methicillin-sensitive S. aureus (MSSA) and MRSA using clinical isolates from China and th

78 MRSA and methicillin-susceptible S. aureus (MSSA) anovaginal colonization in pregnant women, to asse

79 o carried methicillin-susceptible S. aureus (MSSA) as less prevalent flora.

80 MRSA and methicillin-susceptible S. aureus (MSSA) at U.S. wastewater treatment plants.

81 ) CFU/ml of methicillin-sensitive S. aureus (MSSA) attenuation of light transmission was less than 1.

82 tcomes in methicillin-susceptible S. aureus (MSSA) bacteremia.

83 (MRSA) or methicillin-susceptible S. aureus (MSSA) burden in the airways.

84 in MRSA and methicillin-sensitive S. aureus (MSSA) cases.

85 Mu50, and methicillin-susceptible S. aureus (MSSA) controls were included.

86 -susceptible penicillin-resistant S. aureus (MSSA) did not change.

87 only for methicillin-susceptible S. aureus (MSSA) from an enrichment broth.

88 mens grew methicillin-susceptible S. aureus (MSSA) from broth enrichment culture, of which two demons

89 MRSA) and methicillin-susceptible S. aureus (MSSA) in cases of clinical bacteremia may promote approp

90 he place of methicillin-sensitive S. aureus (MSSA) in many communities.

91 rtance of methicillin-susceptible S. aureus (MSSA) in selected communities.

92 ts of ST8 methicillin-susceptible S. aureus (MSSA) isolated in Africa represent a symplesiomorphic gr

93 MRSA) and methicillin-susceptible S. aureus (MSSA) isolates yielded side-scatter (SSC) and fluorescen

94 ng the 39 methicillin-susceptible S. aureus (MSSA) isolates, 29 harbored the R variant.

95 ) and 900 methicillin-susceptible S. aureus (MSSA) isolates.

96 MRSA and methicillin-susceptible S. aureus (MSSA) on TSA II was 12.4% (64/515) and 9.7% (50/515), re

97 MRSA and methicillin-susceptible S. aureus (MSSA) per calendar year, stratified into CO and HO infec

98 ents with methicillin-susceptible S. aureus (MSSA) SSTIs and those with MRSA SSTIs.

99 -positive methicillin-susceptible S. aureus (MSSA) strains has not been investigated.

100 MRSA) and methicillin-susceptible S. aureus (MSSA) strains with different levels of PVL production.

101 MRSA) and methicillin-susceptible S. aureus (MSSA) strains.

102 alence of methicillin-susceptible S. aureus (MSSA) was 84%, while MRSA herd prevalence was 4%.

103 wounds and methicillin-sensitive S. aureus (MSSA) was recovered from 24.

104 (MRSA) or methicillin-susceptible S. aureus (MSSA) were asked to apply mupirocin intranasally twice d

105 SA versus methicillin-susceptible S. aureus (MSSA) were identified.

106 MRSA) and methicillin-susceptible S. aureus (MSSA) with sensitivities of 100% each and specificities

107 es, 16 were methicillin-sensitive S. aureus (MSSA), 207 were methicillin-resistant S. aureus (MRSA) a

108 of MRSA, methicillin-susceptible S. aureus (MSSA), and confounders were included as controls.

109 pposed to methicillin-susceptible S. aureus (MSSA), are more likely to have abused alcohol in the pas

110 iology of methicillin-susceptible S. aureus (MSSA), despite its continued clinical importance.

111 s (MRSA), methicillin-susceptible S. aureus (MSSA), S. aureus, Listeria monocytogenes, whilst the FE

112 olates as methicillin-susceptible S. aureus (MSSA), while one MSSA isolate tested negative for S. aur

113 caused by methicillin-susceptible S. aureus (MSSA).

114 ized with methicillin-susceptible S. aureus (MSSA).

115 .7%) were methicillin-susceptible S. aureus (MSSA).

116 cation as methicillin-susceptible S. aureus (MSSA).

117 d 36 were methicillin-susceptible S. aureus (MSSA).

118 ptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) bacteremia, particularly re

119 thicillin-susceptible Staphylococcus aureus (MSSA) (14), methicillin-resistant Staphylococcus epiderm

120 thicillin-susceptible Staphylococcus aureus (MSSA) (19/24 [79%]) and avoidance of antibiotics for ski

121 Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a morbid infection.

122 thicillin-susceptible Staphylococcus aureus (MSSA) bacteremia, including immediate clearance (<=24 ho

123 thicillin-susceptible Staphylococcus aureus (MSSA) bloodstream infections.

124 thicillin-susceptible Staphylococcus aureus (MSSA) CC398 isolates of known human origin.

125 thicillin-susceptible Staphylococcus aureus (MSSA) clone sequence type (ST) 398 has increasingly been

126 thicillin-susceptible Staphylococcus aureus (MSSA) infection.

127 thicillin-susceptible Staphylococcus aureus (MSSA) infections, beta-lactams are recommended for defin

128 methicillin-sensitive Staphylococcus aureus (MSSA) infections.

129 thicillin-susceptible Staphylococcus aureus (MSSA) isolates from infective endocarditis (IE) and soft

130 thicillin-susceptible Staphylococcus aureus (MSSA) isolates lacking mecA yet testing positive on the

131 thicillin-susceptible Staphylococcus aureus (MSSA) strains and comprised six distinct clones, which c

132 methicillin-sensitive Staphylococcus aureus (MSSA) strains.

133 thicillin-susceptible Staphylococcus aureus (MSSA), and recent studies have suggested similar clinica

134 methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA

135 thicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA

136 meticillin)-sensitive Staphylococcus aureus (MSSA).

137 tetracyclin-resistant Staphylococcus aureus (MSSA, MRSA, and TRSA, respectively) and vancomycin-resis

138 1997 (75 methicillin-susceptible S. aureus [MSSA] and 30 MRSA isolates) in order to investigate for

139 ] and 114 methicillin-susceptible S. aureus [MSSA] isolates) from patients from 127 centers in 34 cou

140 [MRSA], 12 methicillin-sensitive S. aureus [MSSA]) from 2015-2017.

141 and 1 had methicillin-susceptible S. aureus [MSSA]), 8 (2.9%) had zone sizes that measured 19 mm (6 h

142 ed MRSA (or methicillin-sensitive S. aureus [MSSA]).

143 thicillin-susceptible Staphylococcus aureus [MSSA] and 6.3% methicillin-resistant S. aureus [MRSA]),

144 e isolates (methicillin-sensitive S. aureus: MSSA).

145 ing difference in the roles of arlRS between MSSA and MRSA strains is not due to the methicillin resi

146 re no overall prognostic differences between MSSA- and MRSA-PJI, but there was a higher incidence of

147 013, although crude cost differences between MSSA- and MRSA-related pneumonia hospitalizations rose f

148 Most USA200 isolates (both MSSA and MRSA) carried the gene for toxic shock syndrome

149 l successfully allowed the detection of both MSSA and MRSA contaminating important high-touch surface

150 ive MRSA and MSSA infections is similar, but MSSA causes more infections and more deaths in infants t

151 AP patients (n = 15) were mainly infected by MSSA strains (87%), whereas colonized individuals (n = 1

152 ecA (an empty cassette) was correctly called MSSA by the Xpert test.

153 clinical MSSA (n = 103), and nasal carriage MSSA (n = 113), collected over a 19-year period in two M

154 marily to USA300 MRSA, we found that all CC8 MSSA isolates also contained the R variant, suggesting t

155 defined clinical CA-MRSA (n = 77), clinical MSSA (n = 103), and nasal carriage MSSA (n = 113), colle

156 Genotypically, nasal carriage and clinical MSSA isolates were much more diverse than was the CA-MRS

157 compared to the nasal carriage and clinical MSSA strains probably contributed to their enhanced viru

158 eus biofilms formed by a variety of clinical MSSA and MRSA strains and created culture-negative impla

159 genes than did the carriage and the clinical MSSA group (range, 0% to 58%).

160 rienced a stable incidence of CO-MRSA and CO-MSSA bacteremia.

161 patient-days in 2011 [P = .005]), whereas CO-MSSA rates remained stable.

162 l with random intercepts was used to compare MSSA risk factors with those of MRSA.

163 n control prevention efforts should consider MSSA prevention in addition to MRSA.

164 ates had higher SSC and FI readings than did MSSA isolates after 2 h of incubation.

165 Eight MSSA isolates (99.1% sensitivity; 892/900) were assigned

166 , 99.1% were correctly categorized as either MSSA or MRSA.

167 SCCmec types (16.7 to 20.7%); each exceeded MSSA (6.7%; P=0.05).

168 days before and up to 4 days after the first MSSA blood culture was collected.

169 ture between 45 and 365 days after the first MSSA blood culture.

170 707] for MRSA versus $104,121 [$91,314]) for MSSA [P = 0.712]).

171 ibiotic therapy (86% for MRSA versus 91% for MSSA; P = 0.783).

172 eated with either nafcillin or cefazolin for MSSA infection in the outpatient parenteral antimicrobia

173 to 2010 who had positive blood cultures for MSSA.

174 pleted to determine whether risk factors for MSSA and MRSA breast abscess differ.

175 adjusted costs were significantly higher for MSSA-related pneumonia ($40725 vs $38561; P = .045) and

176 Oxacillin was ineffective for MSSA colonization in approximately 30% of the patients,

177 body site; no differences were observed for MSSA.

178 ons compared with nafcillin or oxacillin for MSSA infections complicated by bacteremia.

179 mparison of ceftriaxone versus oxacillin for MSSA osteoarticular infections, there was no difference

180 ded if they had a blood culture positive for MSSA and received definitive therapy with cefazolin, naf

181 The results for MSSA were similar to those for MRSA.

182 was higher for MRSA (15%; 11 of 73) than for MSSA strains (5.2%; 19 of 363) (chi(2) = 9.2; P = 0.01).

183 , exposure of the biosensor to extracts from MSSA-infected mice resulted in 5.6% or less attenuation

184 d electrolyte, a CZE separation of MRSA from MSSA may be completed within 12 min.

185 Few risk factors differentiated MRSA from MSSA SSTIs, and detainee patients with MRSA SSTIs are at

186 of 0.0445 reliably differentiated MRSA from MSSA.

187 y MRSA and to distinguish these strains from MSSA and BORSA, by specifically detecting PBP2a.

188 .6%) had zone sizes of >/=21 mm (all 137 had MSSA).

189 es that measured 19 mm (6 had MRSA and 2 had MSSA), 8 (2.9%) had zone sizes that measured 20 mm (6 ha

190 es that measured 20 mm (6 had MRSA and 2 had MSSA), and 137 (49.6%) had zone sizes of >/=21 mm (all 1

191 SA (from 0.77 to 0.18 per 10 000 PDs) and HO-MSSA (from 1.71 to 0.64 per 10 000 PDs) bacteremia were

192 most of the sites, HO-MRSA decreased and HO-MSSA rates were stable.

193 ifampin may have contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin

194 However, MSSA and MRSA strains that produced high levels of PVL c

195 The distinct human MSSA CC398 spa type, t571, was not present among our MRS

196 We identified MSSA and MRSA bacteremia using International Classificat

197 time to antistaphylococcal therapy (AST) in MSSA infection declined during the study (3.7 days group

198 imilar use of rifampin-based combinations in MSSA- and MRSA-PJI.

199 that ArlRS impacts autolysis differently in MSSA and MRSA strains.

200 Mortality in MSSA bloodstream infection is declining, associated with

201 5% group 2; 26% group 3), while mortality in MSSA infection significantly declined (18% group 1; 18%

202 imization of treatment to impact outcomes in MSSA bacteremia.

203 Treatment strategies to improve survival in MSSA bacteremia are urgently needed.

204 to prevent S aureus infection should include MSSA in addition to MRSA.

205 Invasive MSSA incidence (31.3/100 000) was 1.8 times higher than

206 ospital discharge was similar after invasive MSSA and MRSA infections (risk ratio, 1.19; 95% CI, 0.96

207 oportions of infants who died after invasive MSSA and MRSA infections were similar at 237 of 2474 (9.

208 sociated with healthcare exposures, invasive MSSA is a substantial public health problem in the areas

209 n were similar between infants with invasive MSSA infection and infants with invasive MRSA infection.

210 e mortality data, more infants with invasive MSSA infections (n = 237) died before hospital discharge

211 First-line MSSA therapies (nafcillin, oxacillin, cefazolin) are gen

212 In contrast to those of MRSA, MSSA infectious isolates show wide genetic diversity wit

213 A chart review of 31 patients with MRSA, MSSA, or VRE demonstrated that the Nanosphere BC-GP assa

214 t of the data revealed that the KeyPath MRSA/MSSA blood culture test delivered results a median of 30

215 mpared to standard methods, the KeyPath MRSA/MSSA blood culture test demonstrated a sensitivity, spec

216 e performance of the MicroPhage KeyPath MRSA/MSSA blood culture test was compared to conventional ide

217 Detection of MRSA/MSSA in blood cultures could be reported 10 to 24 h earl

218 esembled MRSA CC398 as found in pigs and not MSSA CC398 as found in humans.

219 ignificantly associated with HO-MRSA but not MSSA BSIs.

220 Overall, 7.1% (64/900) of MSSA isolates showed results compatible with a mecA drop

221 2.34), while there was a higher incidence of MSSA-PJI treatment failure after therapy.

222 ients, 64 (29.8%) had at least 1 incident of MSSA reversion, and 55 (25.6%) reverted to MSSA infectio

223 2 were defined to encompass the majority of MSSA and MRSA signal events, respectively.

224 hibited synergistic action in a rat model of MSSA endocarditis.

225 e autolytic phenotype in the arlRS mutant of MSSA strain Newman could be rescued by a mutation in eit

226 We compared patient outcomes of MSSA osteoarticular infections treated with ceftriaxone

227 The isoelectric points of MSSA and MRSA were found to be the same for both groups

228 E) analysis revealed a diverse population of MSSA strains.

229 The prevalences of MSSA, MRSA, and GBS colonization were 11.8%, 0.6% and 23

230 The overall relative proportion of MSSA was 64.3%.

231 was 33.3%, while the relative proportion of MSSA was 66.7%.

232 el of toxin produced and (2) many strains of MSSA that cause soft-tissue infections produce higher le

233 A retrospective cohort study of MSSA bacteremia was performed in a tertiary hospital fro

234 In this case-control study of MSSA infections, we identified ST398 MSSA as both a majo

235 omycin for empiric and definitive therapy of MSSA bloodstream infections among patients admitted to 1

236 n innate immunomodulator in the treatment of MSSA and MRSA surgical wound infection through enhanceme

237 (63.5%) were of MRSA and 43 (11.4%) were of MSSA; 84.8% of S. aureus isolates were MRSA.

238 llin-susceptible S. aureus (MSSA), while one MSSA isolate tested negative for S. aureus.

239 characteristics and mortality after MRSA or MSSA infection.

240 Infants with invasive MRSA or MSSA infections had similar gestational ages and birth w

241 None of the MRSA or MSSA isolates contained arcA or opp3.

242 red when decisions for outpatient parenteral MSSA treatment are made.

243 One phenotypic MSSA isolate contained an intact SCCmec.

244 lysis, AST within 7 days of initial positive MSSA culture was associated with survival.

245 fits of distinguishing between mecA-positive MSSA and MRSA in clinical reports should be evaluated.

246 o methicillin resistance among mecA-positive MSSA within a patient during antibiotic therapy.

247 Notably, the prevalent MSSA strains (spa t002 and spa t008) are analogous to th

248 icillin-sensitive Staphylococcus aureus (PVL-MSSA) clinical isolates.

249 etection of PVL phages and haplotypes in PVL-MSSA identical to those previously found in PVL-MRSA iso

250 Characterization of PVL-MSSA isolates by multilocus sequence typing (MLST) and s

251 linical study in the treatment of refractory MSSA bacteremia and endocarditis.

252 nt SA (MRSA) and methicillin-susceptible SA (MSSA) infections differ is unknown.

253 he incidence rate for methicillin-sensitive (MSSA) was 2.1 per 100 outpatient-years, and the incidenc

254 tudy of MSSA infections, we identified ST398 MSSA as both a major community- and hospital-associated

255 ed clones (ST47-MSSA, ST30-MRSA-IV[2B], ST45-MSSA, and ST22-MRSA-IV[2B]) compared with none and 1 of

256 nd in 4 of the 5 highest-ranked clones (ST47-MSSA, ST30-MRSA-IV[2B], ST45-MSSA, and ST22-MRSA-IV[2B])

257 nstrated the ability to revert to subsequent MSSA SSTIs with a significant frequency.

258 reference laboratories collected successive MSSA isolates from patients with invasive or superficial

259 resistant (MRSA) or methicillin-susceptible (MSSA) HCAP, based on initial S. aureus isolates.

260 costs of care than methicillin-susceptible (MSSA) infections.

261 ostchallenge with a methicillin-susceptible (MSSA) or a methicillin-resistant (MRSA) strain of S. aur

262 esistant (MRSA) and methicillin-susceptible (MSSA) S. aureus strains.

263 esistant (MRSA) and methicillin-susceptible (MSSA) S. aureus strains.

264 Every tenth MSSA isolate and all MRSA isolates were typed by pulsed-

265 distinct repertoire of virulence genes than MSSA STI isolates from the same region.

266 In 4 of the 6 patients, the MSSA was unrelated to prevalent MRSA, as determined by p

267 egulated in the arlRS mutant of MW2 than the MSSA strain Newman.

268 However, six of these MSSA isolates had the mecA gene confirmed by PCR and seq

269 bacteremia, with a rising proportion due to MSSA (55% group 1; 59% group 2; 63% group 3; P = .03.) T

270 ociated with an increased risk of SSI due to MSSA when compared with prophylaxis with a beta-lactam a

271 f MSSA reversion, and 55 (25.6%) reverted to MSSA infections for the remainder of the study.

272 positive in subsequent SSTIs or reverted to MSSA-positive infections.

273 lusion, vancomycin is commonly used to treat MSSA bacteremia in outpatients receiving chronic dialysi

274 Twelve MSSA isolates tested positive for MRSA by the BD-MRSA PC

275 In all ICU types, MSSA central line-associated BSI incidence declined from

276 S. aureus HCAP, irrespective of MRSA versus MSSA status, is associated with significant mortality an

277 Model outcomes included 12-week MSSA cure, recurrence, and death; allergic reactions inc

278 0: 34 of these strains were MRSA and 12 were MSSA.

279 e colonizing isolates were MRSA, and 14 were MSSA, and the majority of the colonizing isolates belong

280 112 total samples, 27 (24%) and 5 (4%) were MSSA- and MRSA-positive, respectively.

281 The most frequent pathogens were MSSA, methicillin-resistant Staphylococcus aureus, and P

282 ecame more sensitive to ciprofloxacin, while MSSA became more resistant to ciprofloxacin, clindamycin

283 ecame more sensitive to ciprofloxacin, while MSSA demonstrated increased antibiotic resistance to cip

284 uding 15 (0.7%) with MRSA and 22 (1.0%) with MSSA; 115 (5.1%) had Streptococcus pneumoniae Vancomycin

285 1.01-3.18) as significantly associated with MSSA acquisition.

286 that, in recent years, costs associated with MSSA-related infections have converged with and may surp

287 Compared with MSSA-related hospitalizations, MRSA-related hospitalizat

288 This contrasts with MSSA strains, including Newman, SH1000, RN6390, and 8325

289 dex blood culture, 56.1% of outpatients with MSSA bacteremia were receiving vancomycin, and 16.7% of

290 ng vancomycin, and 16.7% of outpatients with MSSA were receiving cefazolin.

291 Patients with MSSA bacteremia and a reported PCN allergy should have t

292 l evaluation and treatment for patients with MSSA bacteremia and reported PCN allergy.

293 Of the 514 patients with MSSA bacteremia, 164 were excluded as they had received

294 d to reduce mortality rates in patients with MSSA bacteremia.

295 For patients with MSSA bloodstream infections, beta-lactams are superior t

296 SA coinfection (9 died) and 22 patients with MSSA coinfection (all survived).

297 s nafcillin or oxacillin among patients with MSSA infections complicated by bacteremia.

298 retrospective cohort study of patients with MSSA osteoarticular infections at a tertiary care hospit

299 Persons with MSSA were more likely than those with MRSA to have no un

300 The adjusted odds ratio (OR) for an SSI with MSSA was 2.79, where vancomycin prophylaxis was administ